Dr. Choueiri Discusses Checkpoint Inhibitors in RCC
In Partnership With:
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).
There are 4 phase III trials of checkpoint inhibitors in RCC, says Choueiri. Immunotherapy agents have already shown success as adjuvant treatments for patients with RCC, with multiple positive trials of CTLA-4 and PD-1 inhibitors.
Choueiri says the next step for checkpoint inhibitors is moving them to the high-risk setting for a set duration of time. There are studies that are accruing, he adds, and if positive, they may change the paradigm for metastatic disease.
In the coming years, RCC is going to be one of the most dynamic, rapidly-changing fields in solid tumor oncology, Choueiri concludes.
